Thinklab Cancer

Retweeting top stories from the thought leaders of @thinklab's Cancer Research community:

[Thinklab Cancer @ThinklabCancer]

The top 50 thought leaders in cancer research: https://t.co/6ZGhFgCsTc (Follow this account for retweets of aggregated top stories)

[Neeraj Agarwal, MD, FASCO @neerajaiims]

@EJonasch @MDAndersonNews & team in @TheLancetOncol —> Pazopanib has promising activity in von Hippel-Lindau disease @VHLAlliance: may be useful in those with growing lesions or to reduce the size of unresectable lesions. https://t.co/e3Dqvm5vTc @montypal @OncHahn @PauloBergerot

[Vincent Rajkumar @VincentRK]

Criteria for High Risk Smoldering Myeloma. Also see Revised Mayo 20-2-20 risk stratification
(20%BMPC, 2g/dL M protein, 20 FLC ratio) #myelomaVR @MayoMyeloma
@mtmdphd @MyelomaTeacher https://t.co/QtiTW3Njgh

[Mehdi Hamadani, MD @MediHumdani]

Very nice analysis by the Wash U group showing persistence of disease-associated mutations at day +30 post allogeneic transplantation are predictive of PFS and relapse risk in MDS patients. #bmtsm #leusm
https://t.co/hWInIxVlWe

[Toni Choueiri, MD @DrChoueiri]

Big news just in...Combo of PD-L1 inh. Avelumab + TKI axitinib is the 1st + IO/TKI PIII that met PFS 1*endpoint irrespective of PD-L1! ⁦@pfizer⁩ ⁦@DanaFarber⁩ ⁦@kcCURE⁩ ⁦@IKCCorg⁩ ⁦@KidneyCancer⁩ Great day for RCC patients! https://t.co/sb8SmzJA6w

[Eric Topol @EricTopol]

Our current approach to #cancer treatment, despite some modest improvements, is still far from precise. @LizSzabo @KHNews gets real & reminds us of the long road ahead. https://t.co/yCVT2W9dmn @nytopinion

[STAT @statnews]

He is analytical and reflective, a lofty dreamer. She will joke and kvetch and needle. Together they have made a life together — and together they are confronting the unthinkable. https://t.co/WtmLPAMiCz

[Corinne Faivre-Finn @finn_corinne]

Provocative article @TheLancetOncol RCTs are being done with the aim of gaining regulatory authorisation, while testing trivial clinical questions. Hence the importance of academics trials https://t.co/GRILp8582V

[d.planchard @dplanchard]

MET exon 14-altered lung cancers express PD-L1, but TMB is low and few responses to PD-1 blockade. ⁦@Annals_Oncology⁩ https://t.co/kC3UsdQxRI

[Brian Kavanagh @BK_radiation]

She’s worn both a hospital gown and a white coat. Now she wants to change how doctors perceive... https://t.co/sehTCPJ6H2 via @statnews

[Nathan A. Pennell MD, PhD, FASCO @n8pennell]

Financial Conflicts of Interest Among Oncologist Authors of Reports of Clinical Drug Trials https://t.co/qSZb9KYMWR

[Eric Topol @EricTopol]

It's high time to transcend @usnews ratings and move to indvidualized ratings of hospitals https://t.co/itF3McCjhX https://t.co/3U0Tw2lg67 @NEJM by @MWFriedberg @RANDCorporation @minhealthnz @BrighamWomens

[Reuters Health @Reuters_Health]

UK rejects Gilead's CAR-T cancer cell therapy as too expensive https://t.co/s6Z53T56iN

[PCF Science @PCF_Science]

Announcing the 2018 Class of PCF Young Investigators! We are so proud to fund these amazing early career scientists who have dedicated their careers to ending #ProstateCancer!
#PCFfunded @PCFnews @manyvscancer
https://t.co/54LDyP2xCp

[Nature Genetics @NatureGenet]

Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors (Miao et al.) https://t.co/QW0IGqjsCL

[Eric Topol @EricTopol]

The #1 supplement—fish oil—taken by tens of millions Americans for billions of dollars/yr. And the latest trial to debunk any value in them.
https://t.co/ULsTjDfcpu @NEJM #ESCCongress

[The Washington Post @washingtonpost]

McCain said in a statement that he has surpassed expectations for his survival since his diagnosis. "But the progress of disease and the inexorable advance of age render their verdict," and the senator has decided to end medical treatment. https://t.co/mrtbnZ1d0L

[Dr Sunil Verma @cancermd]

SOLAR-1 Trial (PI3-k Inh. Alpelisib in Metastatic Breast Cancer) met primary endpont of PFS. Key things to look when data is reported(likely #ESMO18 ): 1. Toxicity profile 2. Magnitude of diff. in PFS 3. Efficacy in CDK4/6 tx patients 4. PI3k test profile https://t.co/ly1UvN9KFc

[Ahmad Tarhini @ATarhiniMDPhD]

Proud to be part of this groundbreaking work & awesome collaborative group / @NEJM / #Melanoma brain metastasis can be definitively teated w #immunotherapy marking a new era in #Immunooncology #Cancerresearch

https://t.co/3uLitd41Tm

@CleClinicMD
#CleClinicCancer
@caseccc

[Benjamin Besse @BenjaminBesseMD]

Our work on Steroids and PD-(L)1 Blockade.
This is not randomized data, and pts that need steroids have probably a poorer prognosis (because of symptomatic brain or bone mets, recent radiotherapy...).
Pts should receive IO when indicated, even w steroids. https://t.co/HKlei2hLew